论文部分内容阅读
目的：制备抗人卵巢癌单克隆抗体ＣＯＣ１８３Ｂ２单域（重链可变区，ＶＨ）抗体，以用于卵巢癌放射免疫显像和导向治疗。方法：将已分离的ＶＨ基因克隆入噬菌粒表达载体ｐＦＵＷ８０中，将重组子转化琥珀突变抑制菌株ＸＬ１ＢＬｕｅ，经辅助噬菌体Ｍ１３Ｋ０７援救后包装成噬菌体颗粒，表达产物通过ＥＬＩＳＡ测定活性。结果：ＶＨ基因克隆入噬菌粒ｐＦＵＷ８０，双酶切鉴定见预期大小片段，表明克隆成功。表达产物经ＥＬＩＳＡ测定，待测值高出阴性对照２．５倍。结论：该抗人卵巢癌小分子单域抗体具有与相应卵巢癌抗原发生特异结合的能力，有望用于卵巢癌放射免疫显像和导向治疗。
Objective: To prepare anti-human ovarian cancer monoclonal antibody COC183 B2 single domain (VH) antibody for radioimmunoimaging and targeted therapy of ovarian cancer. Methods: The isolated VH gene was cloned into the phagemid expression vector pFUW80, and the recombinant was transformed into amber mutant strain XL1BLue. After being rescued by the helper phage M13K07, the recombinant plasmid was packaged into phage particles. The expression product was determined by ELISA. Results: The VH gene was cloned into the phagemid pFUW80. The double digestion showed the expected size of the fragment, indicating that the cloning was successful. The expression product was determined by ELISA, the test value was 2.5 times higher than the negative control. Conclusion: The anti-human ovarian cancer small molecule single domain antibody has the ability of binding specifically with the corresponding ovarian cancer antigen, and is expected to be used for radioimmunoimaging and targeted therapy of ovarian cancer.